Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial

This single-arm, phase II trial is to investigate efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in advanced pancreatic cancer. Nab-paclitaxel was administered at 120 mg/m(2) intravenously on day 1 and 8, S-1 was given twice a day orally on day 1-14 of each 21-day cycle, for...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yan, Zhang, Sui, Han, Quanli, Li, Jie, Yan, Huan, Lv, Yao, Shi, Huaiyin, Liu, Rong, Dai, Guanghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696191/
https://www.ncbi.nlm.nih.gov/pubmed/29190925
http://dx.doi.org/10.18632/oncotarget.21359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696191/
https://www.ncbi.nlm.nih.gov/pubmed/29190925
http://dx.doi.org/10.18632/oncotarget.21359

Ejemplares similares